What does Atrium Therapeutics, Inc. do?
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of…
What is Atrium Therapeutics, Inc.'s P/E and P/B ratio?
Atrium Therapeutics, Inc. has a P/E ratio of -1.5 and a P/B ratio of 0.65.
What is Atrium Therapeutics, Inc.'s debt-to-equity ratio?
Atrium Therapeutics, Inc. has a debt-to-equity ratio of 0.01.
How much does Atrium Therapeutics, Inc. owe compared with what it owns?
Atrium Therapeutics, Inc. owes $0.24 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Atrium Therapeutics, Inc.'s Positivity rank?
Atrium Therapeutics, Inc. is ranked #2,543 of 6,774 companies globally and #838 of 4,000 in United States on PositoAI, with a Positivity Score of 21,399.
Does Atrium Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Atrium Therapeutics, Inc..
Where can I read the latest news about Atrium Therapeutics, Inc.?
Recent headlines about Atrium Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Atrium Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Atrium Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.